Major Review Finds Statins Do Not Cause Most Side Effects Listed in Patient Leaflets
A major review of clinical-trial evidence has provided fresh reassurance about the safety of statins, finding that most of the side effects currently listed in patient information are not actually caused by the medicines.
Statins are among the most widely prescribed medicines in the UK. They lower LDL cholesterol and are commonly used to reduce the risk of heart attack, stroke and other cardiovascular disease in people whose overall risk makes treatment appropriate.
Concerns about side effects have nevertheless followed statins for many years. Muscle pain, memory problems, tiredness, sleep disturbance, liver problems and diabetes have all been associated with the medicines to varying degrees in public discussion and patient information.
The new analysis, led by researchers at Oxford Population Health and published in The Lancet, examined evidence from large double-blind randomised trials to distinguish problems that happen while somebody is taking a statin from problems actually caused by the statin.
That distinction is important.
People taking statins can still experience headaches, fatigue, poor sleep, memory problems or other symptoms. The research suggests that for most of the commonly listed problems, those symptoms occurred at similar rates among people taking a placebo.
What did the statin review examine?
Researchers analysed 23 large randomised controlled trials from the Cholesterol Treatment Trialists' Collaboration.
Nineteen trials compared statins with placebo and included 123,940 participants. A further four trials, involving 30,724 people, compared more intensive statin therapy with less intensive treatment.
Participants were followed for a median of around four and a half years.
The researchers examined 66 potential adverse outcomes that had been listed in product information for five commonly prescribed statins: atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.
Because the studies were double-blind, neither patients nor the researchers managing them knew whether an individual was receiving a statin or placebo.
That makes the trials particularly useful for determining whether symptoms genuinely occur more frequently because of the medication.
Most listed side effects were no more common with statins
The headline finding was striking.
For almost all of the health problems listed as possible statin side effects, there was no statistically significant increase among people taking statins compared with placebo.
The researchers found no meaningful excess of problems such as memory impairment, dementia, depression, sleep disturbance, erectile dysfunction, weight gain, nausea, fatigue or headaches.
Cognitive or memory problems, for example, were reported by around 0.2% of participants each year in both the statin and placebo groups.
That does not mean somebody experiencing memory problems while taking a statin is imagining them.
It means that, across a very large group of patients, those problems occurred at approximately the same rate whether people were taking the medicine or an inactive placebo.
The evidence therefore does not support the conclusion that the statin itself was causing most of those symptoms.
What about muscle pain?
Muscle symptoms need slightly more careful interpretation.
They have long been one of the best-known concerns associated with statins, and the latest study does not overturn previous evidence showing that statins can cause muscle symptoms in a small proportion of patients.
Earlier work by the same research collaboration found that statins were responsible for muscle symptoms in around 1% of people during the first year of treatment, with no meaningful excess after that period.
Importantly, most muscle aches reported by people taking statins were not actually caused by the medicine.
Serious muscle injury is substantially rarer.
This is useful context because somebody developing aches or pains while taking a statin should not automatically conclude that the medicine is responsible.
Equally, persistent or significant symptoms should not simply be ignored.
Anyone concerned about possible medication side effects should discuss them with their GP, pharmacist or prescribing clinician rather than stopping prescribed medication without medical advice.
Statins can slightly increase diabetes risk
There is also genuine evidence that statins can slightly increase blood glucose levels.
For people already at increased risk of type 2 diabetes, this can mean the condition develops somewhat earlier than it otherwise might have done.
That risk has to be considered alongside the cardiovascular benefit of treatment.
Current clinical guidance continues to support statin treatment where cardiovascular benefit outweighs the risk, including in people at elevated diabetes risk.
This is why decisions about statin treatment are based on the individual rather than simply asking whether the medicine has any possible side effects.
A person with a high risk of heart attack or stroke may have considerably more to gain from reducing cardiovascular risk than they have to lose from a small increase in diabetes risk.
What did the research find about the liver?
The review did identify a small increase in abnormal liver blood tests.
Oxford researchers reported an excess risk of around 0.1% for liver blood-test abnormalities.
However, importantly, there was no corresponding increase in serious liver conditions such as hepatitis or liver failure.
The researchers therefore concluded that the small changes seen in liver tests did not generally translate into serious liver disease.
This is quite different from saying statins have no effect on the liver.
It means the evidence needs to distinguish relatively small biochemical changes from significant clinical liver disease.
Why do patient leaflets contain so many possible side effects?
One reason is that establishing whether a medicine genuinely causes a particular symptom can be difficult.
If thousands of people take a medicine for many years, some of them will inevitably experience headaches, tiredness, memory problems, sleep disturbance and many other health complaints.
Those events may be recorded during treatment even where the medicine did not cause them.
Observational research can also struggle to separate association from causation.
The Oxford team therefore used large double-blind randomised trials, where the rate of problems among people receiving statins could be compared directly with people taking placebo.
Of the 66 additional undesirable outcomes investigated, only four showed a statistically significant association with statin treatment after the researchers accounted for multiple comparisons.
The authors have argued that medicine labelling should now be reconsidered so that patients receive information that better reflects the evidence.
Why statins are prescribed
Statins work primarily by reducing LDL cholesterol in the blood.
LDL cholesterol contributes to the development of fatty deposits within arteries, which can increase the risk of heart attacks and strokes.
But prescribing decisions are not normally based on one cholesterol figure in isolation.
A clinician may consider factors such as age, blood pressure, smoking, diabetes, family history, cholesterol measurements and whether cardiovascular disease is already present.
Someone who has already experienced a heart attack or stroke may also be prescribed statins to reduce the risk of another cardiovascular event.
The balance between benefit and potential harm therefore differs from person to person.
The new research strengthens the evidence around safety, but it does not replace an individual medical assessment.
What should somebody taking statins do with this information?
For most people already prescribed statins, the research should be reassuring rather than a reason to change treatment.
It provides stronger evidence that many symptoms historically associated with statins are not actually caused by them.
It does not mean nobody experiences genuine side effects.
Someone who develops new symptoms should still discuss them with an appropriate healthcare professional, particularly if symptoms are severe, persistent or concerning.
A clinician may need to consider other explanations, adjust the dose, review interactions with other medicines or consider another cholesterol-lowering treatment.
The important point is not to stop prescribed treatment solely because a symptom appears on a long list of possible side effects.
What does this mean for private medical insurance?
The research also provides a useful example of the difference between medical treatment and private medical insurance.
Private medical insurance does not normally pay for everyday repeat prescriptions or routine long-term management of chronic medical conditions.
Someone taking statins to manage cholesterol or ongoing cardiovascular risk should therefore not assume that a PMI policy will pay indefinitely for the medication, routine cholesterol tests or regular chronic-condition monitoring.
Our guide to what private medical insurance covers and what it doesn't explains why PMI is primarily designed around eligible private diagnosis and treatment of new acute conditions rather than routine long-term healthcare.
Cholesterol and cardiovascular risk can become a pre-existing condition issue
Medical history also matters when somebody applies for private medical insurance.
If someone already has diagnosed high cholesterol, cardiovascular disease, diabetes or another ongoing medical problem before their policy begins, treatment connected with that condition may be treated as pre-existing or chronic.
That does not necessarily mean they cannot buy PMI.
A policy may still provide useful cover for unrelated new eligible conditions.
But existing symptoms, previous investigations, medication and diagnoses need to be considered when assessing what the policy would actually cover.
Our guide to private medical insurance with pre-existing conditions explains how full medical underwriting, moratorium underwriting and exclusions can affect the position.
The distinction is particularly relevant for someone already taking long-term medication.
Buying insurance after treatment has begun does not normally transform that existing treatment into an insured future claim.
Chronic condition management is usually different
High cholesterol, diabetes and some cardiovascular conditions can require ongoing monitoring for many years.
That is the type of healthcare that private medical insurance commonly treats differently from a new acute medical problem.
Routine medication, regular blood testing and continuing management of established chronic disease will often remain NHS-led.
Our guide to what isn't covered by private medical insurance explains why chronic-condition management is one of the areas customers should understand before choosing cover.
PMI may still become relevant if a person later develops a separate eligible condition requiring specialist consultation, diagnostics or planned treatment, depending on the policy.
It is therefore better to think of private insurance as complementing long-term NHS healthcare rather than replacing it.
Private GP access can provide another route to medical advice
Some private medical insurance policies now include access to digital or private GP services.
That can provide a convenient way to discuss a new medical concern, obtain advice or determine whether further investigation is appropriate.
However, private GP access should not be confused with unlimited private management of an existing chronic condition.
Our guide to private GP access through private medical insurance explains why the initial appointment and whatever happens afterwards need to be considered separately.
A GP service may be included while medication, monitoring or treatment relating to an established condition remains outside the insured benefits.
Heart attacks and strokes remain emergencies
Statins are prescribed partly because reducing cardiovascular risk can help prevent heart attacks and strokes.
If somebody develops symptoms suggesting either condition, private medical insurance should not delay emergency treatment.
PMI does not normally replace A&E, ambulance services or emergency stabilisation.
Our guide to whether private medical insurance covers emergency treatment explains why suspected heart attacks, strokes and other medical emergencies should be dealt with through the appropriate NHS emergency service.
Private insurance may sometimes become relevant later for eligible planned follow-up care, but the emergency itself remains an NHS pathway.
What the new evidence really tells us
The most useful conclusion from the study is not that statins are completely free from side effects.
No effective medicine should be described that way.
Instead, the evidence suggests that the list of health problems commonly attributed to statins has become much broader than the problems the strongest clinical evidence actually shows they cause.
There remains evidence of a small increase in muscle symptoms, modest changes in blood glucose and small increases in some liver-test abnormalities.
But the large randomised trials do not support causal links between statins and most of the other conditions listed in patient information, including memory loss, depression, sleep problems and sexual dysfunction.
For patients who have been advised to take statins because of cardiovascular risk, that provides significant reassurance.
It also reinforces the importance of discussing treatment concerns with a healthcare professional rather than making decisions based on a symptom list alone.
For anyone considering private medical insurance alongside NHS care, the same principle applies: understand exactly what the policy is designed to cover, what counts as pre-existing or chronic, and which parts of ongoing healthcare will continue to rely on the NHS.
You can read our wider guide to what private medical insurance covers or request a PMI quote if you want to compare policy options.
Sources: Cholesterol Treatment Trialists' Collaboration, Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials, The Lancet, published online 5 February 2026; University of Oxford, 6 February 2026. This article is for general information only and does not constitute medical or insurance advice. Anyone concerned about statin treatment, side effects or cardiovascular risk should speak to an appropriate healthcare professional.
